相关实验视频

Updated: May 6, 2026

Murine Model of CD40-activation of B cells

Murine Model of CD40-activation of B cells

Published on: March 6, 2010

CD40/PI3K/FOXO1轴重新布线驱动微环境依赖的BIM沉默,以维持淋巴瘤生长和存活率

Candice Madiot¹, Céline Bellanger¹, Christelle Dousset¹

¹Nantes Université, CNRS, CHU de Nantes, Inserm, Nantes, France.

|February 19, 2026

概括

瘤微环境 (TME) 下调BIM,一个关键蛋白质,在地幔细胞淋巴瘤 (MCL). 这种抵抗机制可以通过像双特异性T细胞参与剂这样的免疫疗法来克服.

科学领域:

在瘤学瘤学.
细胞生物学细胞生物学
免疫学免疫学免疫学

背景情况:

瘤微环境 (TME) 显著影响癌症的进展和治疗耐药性.
BCL2家族蛋白质是B细胞恶性瘤中亡和治疗反应的关键调节者.
薄膜细胞淋巴瘤 (MCL) 是一种具有有限治疗选择的侵袭性B细胞瘤.

研究的目的:

为了研究在MCL TME.内对亲细胞亡蛋白BIM的调节.
阐明推动MCLBIM下调的机制.
评估BIM损失对MCL细胞存活率和治疗敏感性的功能影响.

主要方法:

循环与淋巴结MCL样本的比较分析.
模仿TME的ex vivo共同培养系统.
涉及PI3K/AKT通路和FOXO1转录活性的机制研究.
在CRISPR/Cas9基因编辑中删除BIM.
药物耐药性和对双特异性T细胞参与剂的反应的评估.

主要成果:

与正常B细胞相比,TME中的恶性MCL细胞表现出选择性的BIM下调.
这种下调是通过 CD40L 依存的 PI3K/AKT 路径重新连接来调节的,抑制 FOXO1.1.
通过CRISPR/Cas9介导的BIM删除促进了MCL细胞的自主扩张以及对化疗和向药物的耐药性.
双特异性T细胞参与剂有效地杀死MCL细胞,无论BIM表达如何.

结论:

TME积极抑制MCL中的BIM表达,促进生存和治疗耐药性.
针对BIM是不足以克服TME驱动的阻力.
免疫疗法,如双特异性T细胞参与剂,有望克服TME诱导的MCL中亡性抵抗.

更多相关视频

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...